Radiopharm Theranostics, Ltd

This early-stage study tests a new drug called 161Tb-RAD402 in 73 men with castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The drug is a radioactive antibody designed to seek out and attack cancer cells by targeting a protein called fr…

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…

This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and destroy cancer cells that have a protein called PD-L1 on their surface. The study will involve 30 adults with advanced solid tumors (like lung, breast, or sk…

This early-phase trial tests a new drug called 177Lu-RAD202, which is a radioactive antibody designed to seek out and deliver radiation directly to HER2-positive cancer cells. The study involves 30 adults with advanced solid tumors that have not responded to standard treatments. …

This early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it …